Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Sorio, Claudio ^a   Mafficini, Andrea ^a   Furlan, Federico ^b   Barbi, Stefano ^a   Bonora, Antonio ^a   Brocco, Giorgio ^c   Blasi, Francesco ^b   Talamini, Giorgio ^a   Bassi, Claudio ^a   Scarpa, Aldo ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY AND HOSPITAL TRUST OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CREATININE; UROKINASE RECEPTOR;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHRONIC PANCREATITIS; CONTROLLED STUDY; CREATININE URINE LEVEL; DIAGNOSTIC VALUE; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PROTEIN URINE LEVEL; REFERENCE VALUE; SEX DIFFERENCE; URINALYSIS; ADENOCARCINOMA; AGED; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PANCREAS CARCINOMA; PANCREAS TUMOR; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK; URINE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ODDS RATIO; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR;

EID: 80053996648     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-448     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
2. Herszenyi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 2010, 14:249-258.
3. Burris HA. Recent updates on the role of chemotherapy in pancreatic cancer. Semin Oncol 2005, 32:S1-3.
4. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004, 363:1049-1057. 10.1016/S0140-6736(04)15841-8, 3062508, 15051286.
5. Ghaneh P, Smith R, Tudor-Smith C, Raraty M, Neoptolemos JP. Neoadjuvant and adjuvant strategies for pancreatic cancer. Eur J Surg Oncol 2008, 34:297-305. 10.1016/j.ejso.2007.07.204, 17936564.
6. Xiong HQ, Carr K, Abbruzzese JL. Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions. Drugs 2006, 66:1059-1072. 10.2165/00003495-200666080-00003, 16789792.
7. Kern S, Hruban R, Hollingsworth MA, Brand R, Adrian TE, Jaffee E, Tempero MA. A white paper: the product of a pancreas cancer think tank. Cancer Res 2001, 61:4923-4932.
8. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 2005, 31:164-169. 10.1016/j.ejso.2004.09.007, 15698733.
9. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006, 12:442-446. 10.1158/1078-0432.CCR-05-0564, 16428484.
10. Goggins M. Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol 2007, 34:303-310. 10.1053/j.seminoncol.2007.05.003, 2175209, 17674958.
11. Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985, 100:86-92. 10.1083/jcb.100.1.86, 2113459, 3880760.
12. Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RK. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 1985, 82:4939-4943. 10.1073/pnas.82.15.4939, 390473, 2991901.
13. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002, 3:932-943. 10.1038/nrm977, 12461559.
14. Llinas P, Le Du MH, Gardsvoll H, Dano K, Ploug M, Gilquin B, Stura EA, Menez A. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. Embo J 2005, 24:1655-1663. 10.1038/sj.emboj.7600635, 1142576, 15861141.
15. Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des 2003, 9:1499-1528. 10.2174/1381612033454630, 12871065.
16. Andolfo A, English WR, Resnati M, Murphy G, Blasi F, Sidenius N. Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thromb Haemost 2002, 88:298-306.
17. Beaufort N, Leduc D, Rousselle JC, Magdolen V, Luther T, Namane A, Chignard M, Pidard D. Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J Immunol 2004, 172:540-549.
18. Hoyer-Hansen G, Ploug M, Behrendt N, Ronne E, Dano K. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem 1997, 243:21-26. 10.1111/j.1432-1033.1997.0021a.x, 9030717.
19. Koolwijk P, Sidenius N, Peters E, Sier CF, Hanemaaijer R, Blasi F, van Hinsbergh VW. Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. Blood 2001, 97:3123-3131. 10.1182/blood.V97.10.3123, 11342439.
20. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997, 9:714-724. 10.1016/S0955-0674(97)80126-3, 9330876.
21. Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 2000, 12:613-620. 10.1016/S0955-0674(00)00140-X, 10978898.
22. Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, Blasi F. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA 2002, 99:1359-1364. 10.1073/pnas.022652999, 122195, 11818541.
23. Furlan F, Orlando S, Laudanna C, Resnati M, Basso V, Blasi F, Mondino A. The soluble D2D3(88-274) fragment of the urokinase receptor inhibits monocyte chemotaxis and integrin-dependent cell adhesion. J Cell Sci 2004, 117:2909-2916. 10.1242/jcs.01149, 15173320.
24. Pedersen N, Schmitt M, Ronne E, Nicoletti MI, Hoyer-Hansen G, Conese M, Giavazzi R, Dano K, Kuhn W, Janicke F, et al. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 1993, 92:2160-2167. 10.1172/JCI116817, 288394, 8227331.
25. Mizukami IF, Faulkner NE, Gyetko MR, Sitrin RG, Todd RF. Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood 1995, 86:203-211.
26. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Dano K, Brunner N. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999, 91:869-874. 10.1093/jnci/91.10.869, 10340907.
27. Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Dano K, Brunner N, Blasi F. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998, 58:1843-1849.
28. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Hofler H, Janicke F, Graeff H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997, 78:285-296.
29. Sier CF, Sidenius N, Mariani A, Aletti G, Agape V, Ferrari A, Casetta G, Stephens RW, Brunner N, Blasi F. Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest 1999, 79:717-722.
30. Sier CF, Nicoletti I, Santovito ML, Frandsen T, Aletti G, Ferrari A, Lissoni A, Giavazzi R, Blasi F, Sidenius N. Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. Thromb Haemost 2004, 91:403-411.
31. Casella R, Shariat SF, Monoski MA, Lerner SP. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma. Cancer 2002, 95:2494-2499. 10.1002/cncr.10989, 12467062.
32. Cantero D, Friess H, Deflorin J, Zimmermann A, Brundler MA, Riesle E, Korc M, Buchler MW. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 1997, 75:388-395. 10.1038/bjc.1997.63, 2063363, 9020484.
33. Harvey SR, Hurd TC, Markus G, Martinick MI, Penetrante RM, Tan D, Venkataraman P, DeSouza N, Sait SN, Driscoll DL, Gibbs JF. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. Clin Cancer Res 2003, 9:4935-4943.
34. Hildenbrand R, Niedergethmann M, Marx A, Belharazem D, Allgayer H, Schleger C, Strobel P. Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group. Am J Pathol 2009, 174:2246-2253. 10.2353/ajpath.2009.080785, 2684189, 19435784.
35. Talamini G, Zamboni G, Salvia R, Capelli P, Sartori N, Casetti L, Bovo P, Vaona B, Falconi M, Bassi C, Scarpa A, Vantini I, Pederzoli P. Intraductal papillary mucinous neoplasms and chronic pancreatitis. Pancreatology 2006, 6:626-634. 10.1159/000097605, 17135772.
36. Talamini G, Bassi C, Falconi M, Sartori N, Vaona B, Bovo P, Benini L, Cavallini G, Pederzoli P, Vantini I. Smoking cessation at the clinical onset of chronic pancreatitis and risk of pancreatic calcifications. Pancreas 2007, 35:320-326. 10.1097/mpa.0b013e31812e965e, 18090237.
37. Resnati M, Pallavicini I, Daverio R, Sidenius N, Bonini P, Blasi F. Specific immunofluorimetric assay detecting the chemotactic epitope of the urokinase receptor (uPAR). J Immunol Methods 2006, 308:192-202. 10.1016/j.jim.2005.10.013, 16386755.
38. Ronne E, Behrendt N, Ploug M, Nielsen HJ, Wollisch E, Weidle U, Dano K, Hoyer-Hansen G. Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay. J Immunol Methods 1994, 167:91-101. 10.1016/0022-1759(94)90078-7, 8308290.
39. R Development Core Team R: A Language and Environment for Statistical Computing 2009, Vienna, Austria: R Foundation for Statistical Computing, 2.10, R Development Core Team.
40. Therneau T, Lumley T. survival: Survival analysis, including penalised likelihood 2009, 2.35.8.